{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:27:52Z","timestamp":1786958872236,"version":"build-2736575974"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Impaired renal urate excretion is a major mechanism underlying hyperuricemia and gout, with urate transporter 1 (URAT1), encoded by SLC22A12, playing a central role in proximal tubular urate reabsorption. This review summarizes the biological relevance of URAT1, the pharmacological evolution of URAT1 inhibitors, and their clinical implications in urate-lowering therapy. Evidence from transporter biology, structural pharmacology, pharmacokinetic and pharmacodynamic studies, and clinical trials was narratively synthesized. URAT1 inhibitors lower serum urate by blocking renal tubular urate reabsorption and increasing urinary urate excretion, providing a mechanism complementary to xanthine oxidase inhibition. Early uricosuric agents established the clinical value of this approach but are limited by non-selective transporter inhibition, tolerability concerns, drug\u2013drug interactions, and organ-specific safety issues. Newer selective URAT1 inhibitors have been developed to improve transporter selectivity, pharmacodynamic precision, and clinical usability. Current evidence supports selective URAT1 inhibition as an effective strategy for achieving serum urate targets, particularly in underexcretion-type hyperuricemia, while renal monitoring and prevention of uric acid stone formation remain important. Emerging agents may further expand treatment options, but long-term renal, hepatic, and cardiovascular safety require further validation. Overall, URAT1 inhibition represents a rational and increasingly precise therapeutic strategy for hyperuricemia and gout, with future research needed to define its long-term outcomes, comparative effectiveness, pharmacogenomic predictors, and broader cardio-renal-metabolic implications.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1915148","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:56:40Z","timestamp":1786957000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["URAT1 inhibition in hyperuricemia and gout: from transporter biology to clinical precision therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Guangtao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.04.008","article-title":"Gout epidemiology and comorbidities","volume":"50","author":"Singh","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(24)00117-6","article-title":"Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"6","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","article-title":"Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options","volume":"15","author":"Bardin","year":"2017","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rdc.2014.07.002","article-title":"Gout: a review of nonmodifiable and modifiable risk factors","volume":"40","author":"MacFarlane","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"B5","article-title":"Diagnosis, treatment, and prevention of gout","volume":"90","author":"Hainer","year":"2014","journal-title":"Am Fam Physician"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.925219","article-title":"Review of urate-lowering therapeutics: from the past to the future","volume":"13","author":"Jenkins","year":"2022","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000861","article-title":"Update on gout management: what is old and what is new","volume":"34","author":"Afinogenova","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174291","article-title":"A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: current therapeutic options and potential applications","volume":"907","author":"Song","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1676727","article-title":"Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019)","volume":"29","author":"Dong","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5049\/ebp.2021.19.1.1","article-title":"Urate transporters in the kidney: what clinicians need to know","volume":"19","author":"Chung","year":"2021","journal-title":"Electrolyte Blood Press"},{"key":"B11","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.42838","article-title":"Hyperuricemia subtypes classified according to renal uric acid handling manifesting distinct phenotypic and genetic profiles in people with gout","volume":"76","author":"Qi","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00603.2018","article-title":"A model of uric acid transport in the rat proximal tubule","volume":"316","author":"Edwards","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64654","article-title":"Allopurinol: clinical considerations in the development and treatment of Stevens-Johnson syndrome, toxic epidermal necrolysis, and other associated drug reactions","volume":"16","author":"Dillman","year":"2024","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol: population-based cohort study","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01006-3","article-title":"Mechanisms and rationale for uricase use in patients with gout","volume":"19","author":"Schlesinger","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41467-025-56843-5","article-title":"Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1","volume":"16","author":"Guo","year":"2025","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13980","article-title":"Uric acid transport, transporters, and their pharmacological targeting","volume":"238","author":"Adomako","year":"2023","journal-title":"Acta Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/hy1101.092839","article-title":"Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism","volume":"38","author":"Mazzali","year":"2001","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1186-z","article-title":"Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2","volume":"20","author":"Mancikova","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2500","article-title":"Genome-wide association analyses identify 18 new loci associated with serum urate concentrations","volume":"45","author":"K\u00f6ttgen","year":"2013","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.3390\/ijms24098455","article-title":"Pathogenic variants of SLC22A12 (URAT1) and SLC2A9 (GLUT9) in Spanish patients with renal hypouricemia: founder effect of SLC2A9 variant c.374C>T; p.(T125M)","volume":"24","author":"Perdomo-Ramirez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.40929","article-title":"Effects of allopurinol dose escalation on bone erosion and urate volume in gout: a dual-energy computed tomography imaging study within a randomized, controlled trial","volume":"71","author":"Dalbeth","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B29","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5738900","article-title":"Recent updates of natural and synthetic URAT1 inhibitors and novel screening methods","volume":"2021","author":"Chen","year":"2021","journal-title":"Evid Based Complement Alternat Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1124\/jpet.124.002096","article-title":"Unique binding sites of uricosuric agent dotinurad for selective inhibition of renal uric acid reabsorptive transporter URAT1","volume":"390","author":"Fujita","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105826","article-title":"Optimizing gout treatment: a comprehensive review of current and emerging uricosurics","volume":"92","author":"Kaufmann","year":"2025","journal-title":"Joint Bone Spine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2165911","article-title":"Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)","volume":"32","author":"Shi","year":"2022","journal-title":"Expert Opin Ther Pat"},{"key":"B34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","article-title":"Benzbromarone in the treatment of gout","volume":"59","author":"Azevedo","year":"2019","journal-title":"Adv Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/13813455.2019.1610779","article-title":"Natural products for the management of hyperuricaemia and gout: a review","volume":"127","author":"El-Tantawy","year":"2021","journal-title":"Arch Physiol Biochem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"897190017734427","DOI":"10.1177\/0897190017734427","article-title":"Lesinurad, a selective URAT-1 inhibitor with a novel mechanism in combination with a xanthine oxidase inhibitor, for hyperuricemia associated with gout","volume":"1","author":"Huneycutt","year":"2017","journal-title":"J Pharm Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1755251","article-title":"Recent approaches to gout drug discovery: an update","volume":"15","author":"Otani","year":"2020","journal-title":"Expert Opin Drug Discov"},{"key":"B40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2165\/00003088-198207010-00003","article-title":"Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone","volume":"7","author":"Pedersen","year":"1982","journal-title":"Clin Pharmacokinet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01851-6","article-title":"A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/cells13050450","article-title":"A possible therapeutic application of the selective inhibitor of urate transporter 1, dotinurad, for metabolic syndrome, chronic kidney disease, and cardiovascular disease","volume":"13","author":"Yanai","year":"2024","journal-title":"Cells"},{"key":"B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10157-020-01849-0","article-title":"Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.37349\/emd.2024.00077","article-title":"How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present","volume":"2","author":"Keenan","year":"2024","journal-title":"Explor Musculoskeletal Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2020.03.002","article-title":"Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor","volume":"35","author":"Omura","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s10157-020-01855-2","article-title":"A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males","volume":"24","author":"Furihata","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.43261","article-title":"Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomized, multicenter, double-blind, phase 3 trial in China","volume":"77","author":"Sun","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10157-019-01831-5","article-title":"Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout","volume":"24","author":"Hosoya","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-021-02115-7","article-title":"Comparative study of a novel selective urate reabsorption inhibitor \"dotinurad\" among patient groups with different stages of renal dysfunction","volume":"25","author":"Takahashi","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06356-z","article-title":"Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s40001-023-01208-1","article-title":"Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)","volume":"28","author":"Tanaka","year":"2023","journal-title":"Eur J Med Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1538003","article-title":"Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and\/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials","volume":"29","author":"Fitz-Patrick","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key100","article-title":"Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study","volume":"57","author":"Shiramoto","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/annrheumdis-2021-eular.1284","article-title":"POS1130 pharmacokinetics and serum urate lowering effects of AR882, a novel, potent and selective uricosuric agent, in patients with gout","volume":"80","author":"Shen","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2023-eular.3251","article-title":"OP0295 a 12-week, randomized, double-blinded, placebo-controlled, phase 2b study of safety, tolerability and efficacy of AR882 in gout patients","volume":"82","author":"Wei","year":"2023","journal-title":"Ann Rheumatic Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.304","article-title":"OP0302 ruzinurad for hyperuricemia associated with primary gout: a multicenter, randomized, double-blind, active-controlled, phase 3 study","volume":"84","author":"Ding","year":"2025","journal-title":"Ann Rheumatic Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5419890","article-title":"A brief review of natural products with urate transporter 1 inhibition for the treatment of hyperuricemia","volume":"2022","author":"Yuan","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.109977","article-title":"A review on gout: Looking back and looking ahead","volume":"117","author":"Tao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-024-01023-1","article-title":"Transport mechanism and structural pharmacology of human urate transporter URAT1","volume":"34","author":"Dai","year":"2024","journal-title":"Cell Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1915148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:56:41Z","timestamp":1786957001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1915148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2026.1915148"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1915148","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1915148"}}